Investor Overview Press Releases May 8, 2026 Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference May 7, 2026 Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update April 28, 2026 Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor View all » Events May 14, 20269:35 AM PDT Bank of America 2026 Global Healthcare Conference Apr 28, 20268:30 AM EDT Aclaris Clinical Program Update Apr 14, 202612:00 PM EDT H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference View all » Feature Presentation May 2026 Corporate Overview
May 7, 2026 Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
April 28, 2026 Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
